Bordetella bronchiseptica; Erysipelothrix rhsiopathiae; Haemophilus parasuis; Pasteurella spp., P. multocida; Mycoplasma spp., M. hyopneumoniae, M. hyorhinis; Swine influenza virus ; PRRS virus; Porcine circovirus; Porcine parvovirus; Pseudorabies virus; Eperythrozoonosis suis; Mycobacterium spp., M. avium , M. intracellulare, M. bovis; Porcine respiratory corona virus; Arcanobacterium pyogenes; Porcine adenovirus; Clasical swine fever; Porcine cytomegalovirus; African swine fever; Escherichia coli; Streptococcus spp., S. suis, S. porcinus, S. dysgalactiae, S. dysgalactiae subsp. equisimilis; Brucella suis, Brucella suis biovars 1, 2 and 3; Leptospira spp., L. australis, L. canicola, L. grippotyphosa, L. pomona, L. icterohaemorrhagicae, L. interrogans, L. tarassovi, L. hardjo, L. sejroe; Encephalomyocarditis virus; Hemagglutinating encephalomyelitis virus; Japanese encephalitis virus; West Nile virus; Reovirus; Rúbulavirus; Menangle virus; Nipah virus; Vesicular stomatitis virus; Virus of vesicular exanthema of swine; Swine pox virus; Swine herpes virus; and Staphylococcus hyicus; in two or more containers.

8. The kit according to claim ~~7~~ 6 or ~~8~~ 7, wherein the kit further comprises an instruction letter for the treatment and/or prophylaxis of diseases of swine.

9. ~~A method for the prophylaxis or treatment of diseases caused by *L. intracellularis*, and one or more further swine pathogenic microorganism(s), wherein~~ Use of *L. intracellularis* antigen ~~is administered to a non-human animal in need thereof~~ together with one or more further immunological active components of at least

one further disease-causing organism for swine selected from the group consisting of: Salmonella spp., S. typhimurium, S.choleraesuis; Astroviruses; Rotavirus; Transmissible gastroenteritis virus; Brachyspira spp., B. hyodysenteriae, B. pilosicoli; Clostridium spp., in particular C. difficile, C. perfringens types A, B and C, C. novyi, C. septicum, C. tetani; Porcine enteric picornaviruses; Porcine enteric caliciviruses; Actinobacillus pleuropneumonia; Bordetella bronchiseptica; Erysipelothrix rhsiopathiae; Haemophilus parasuis; Pasteurella spp., P. multocida; Mycoplasma spp., M. hyopneumoniae, M. hyorhinis; Swine influenza virus ; PRRS virus; Porcine circovirus; Porcine parvovirus; Pseudorabies virus; Eperythrozoonosis suis; Mycobacterium spp., M. avium , M. intracellulare, M. bovis; Porcine respiratory corona virus; Arcanobacterium pyogenes; Porcine adenovirus; Clasical swine fever; Porcine cytomegalovirus; African swine fever; Escherichia coli; Streptococcus spp., S. suis, S. porcinus, S. dysgalactiae, S. dysgalactiae subsp. equisimilis; Brucella suis, Brucella suis biovars 1, 2 and 3; Leptospira spp., L. australis, L. canicola, L. grippotyphosa, L. pomona, L. icteroliaemorrhagicae, L. interrogans, L. tarassovi, L. hardjo, L. sejroe; Encephalomyocarditis virus; Hemagglutinating encephalomyelitis virus; Japanese encephalitis virus; West Nile virus; Reovirus; Rubulavirus; Menangle virus; Nipah virus; Vesicular stomatitis virus; Virus of vesicular exanthema of swine; Swine pox virus; Swine herpes virus; and Staphylococcus hyicus in the manufacture of a combination vaccine for the prophylaxis or treatment of diseases caused by *L. intracellularis*, and one or more further swine pathogenic microorganism(s).